SCHEMBL1814748

SCHEMBL1814748

CN(C)CCOc1ccc2[nH]ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.56
PDGFRB P09619 2/20 0.54
PDGFRA P16234 2/20 0.54
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HDAC1 Q13547 1/20 0.51
FLT3 P36888 1/20 0.51
MAOA P21397 2/20 0.49
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA7 P36544 1/20 0.48
CHRNA10 Q9GZZ6 1/20 0.48
CHRNA9 Q9UGM1 1/20 0.48
NUAK1 O60285 1/20 0.47
CHRNB2 P17787 1/20 0.46
CHRNA4 P43681 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
NR4A2 P43354 1/20 0.46
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3794813 0.82 LTA4H (0.60) LTA4HHDAC1MAOACHRNB4CHRNA3
SCHEMBL3793622 0.82 LTA4H (0.60) LTA4HKDM4EHDAC1MAOACHRNB4
SCHEMBL22510158 0.81 MEN1 (0.56) LTA4HPDGFRBPDGFRAKDM4EALDH1A1
SCHEMBL1196073 0.81 LTA4H (0.58) LTA4HPDGFRBHDAC1MAOACHRNB4
SCHEMBL5736927 0.80 HDAC1 (0.53) LTA4HKDM4EHDAC1MAOACHRNB4
SCHEMBL1544837 0.79 LTA4H (0.60) LTA4HHDAC1MAOACHRNB4CHRNA3
SCHEMBL14481578 0.79 LTA4H (0.60) LTA4HHDAC1MAOACHRNB4CHRNA3
SCHEMBL1196091 0.78 LTA4H (0.55) LTA4HPDGFRBPDGFRAALDH1A1HDAC1
SCHEMBL19884908 0.78 LTA4H (0.56) LTA4HHDAC1MAOACHRNB4CHRNA3
SCHEMBL31543714 0.78 LTA4H (0.56) LTA4HHDAC1MAOACHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119707772-A USP14 covalent inhibitor and preparation method and application thereof 浙江大学 2025-03-28 CN disclosed
US-20230321130-A1 Senolytic Compositions and Uses Thereof Rubedo Life Sciences, Inc. 2023-10-12 US disclosed
US-20180051031-A1 SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE THE SCRIPPS RESEARCH INSTITUTE 2018-02-22 US disclosed
WO-2011051484-A1 FLUORESCENCE DYES GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENLICHEN RECHTS (DE) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321130-A1 Senolytic Compositions and Uses Thereof SENP3, SENP6, SENP1 LTA4H 2422/4885PDGFRB 2631/4885PDGFRA 3439/4885
US-20180051031-A1 SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE CD22, GDI2, GDI1 LTA4H 2729/4885PDGFRB 2694/4885PDGFRA 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.